Lipocine Inc. (LPCN) analyst actions
Rating and price-target actions on LPCN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the LPCN overview →
2 measured LPCN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression | Press release | +0.00% | +0.91% | |
| Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 | Press release | — | -0.57% |
Keep exploring
More LPCN: earnings → · SEC filings → · LPCN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PROVECTUS BIOPHARMS (PVCT) | 220 | +0.01% | 50% |
| TG Therapeutics, Inc. (TGTX) | 220 | -0.06% | 47% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
| AngioDynamics, Inc. (ANGO) | 218 | +0.33% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.